Although positive modulation of SV2A is a novel approach for the treatment of AD, the current 12‐week trial failed to show a significant difference from placebo; a study duration exceeding 12 weeks may be necessary to reliably identify therapeutic benefits conferred by ABBV‐552,33 especially if those effects are modest. The gene discussed is SV2A; the disease is Alzheimer disease.